Newborn babies to be screened for spinal muscular atrophy

Newborn babies across England will begin to be tested for spinal muscular atrophy (SMA) from Thursday, marking the start of a national trial. The initiative seeks to evaluate the effectiveness of incorporating SMA screening into the established blood spot test programme for newborns and its impact on patient care.

Spinal muscular atrophy is a rare genetic condition that affects approximately 60 to 70 babies born in England each year. It can lead to severe muscle weakness, impacting a baby's ability to move, breathe, and swallow. Early intervention is critical, as treatments for SMA are most effective when administered before symptoms become apparent.

Trial Rollout and Aims

The trial will gather evidence on the practicalities of screening, including the speed of referral for specialist assistance. This data will inform the UK National Screening Committee's decision on whether to permanently integrate SMA screening into the routine newborn blood spot test. Currently, this test screens for 10 rare conditions, some of which can be life-threatening.

Research suggests that widespread screening in England could prevent around three early deaths annually, stop approximately two babies from requiring permanent ventilation, and enable around 37 babies with SMA to live largely normal lives. The rollout will see new laboratories joining the programme at intervals until October 2027, with the objective of offering SMA screening to all babies born in England by spring 2028.

The first phase of the rollout includes Birmingham, followed by Manchester, South West Thames, South East Thames, Great Ormond Street Hospital, and Sheffield. Six further laboratories in Portsmouth, Oxford, Cambridge, Bristol, Leeds, and Liverpool will be added subsequently.

Campaigning and Wider Implications

The introduction of SMA screening follows years of campaigning by the SMA community. Louise Parkes, chief executive at Great Ormond Street Hospital Charity, stated that the trial means more babies will be diagnosed before symptoms appear, offering them the best chance of receiving effective treatment before irreversible damage occurs. She highlighted the need for a screening system that can adapt quickly to advances in science and treatment.

Andy Fletcher, chief executive of Muscular Dystrophy UK, raised concerns about babies in Wales and Northern Ireland being excluded if similar programmes are not introduced, noting that Scotland has already commenced screening. He emphasised that a postcode lottery for screening is unacceptable and that babies in all parts of the UK deserve equal opportunities for early diagnosis.

Dr Harrison Carter, director of screening at NHS England, described the trial as a potentially life-changing moment for parents in Birmingham, whose babies are the first to benefit. He reiterated that early diagnosis offers the best chance of benefiting from NHS treatments, helping to prevent severe muscle weakness and enabling children to reach developmental milestones. He confirmed that the NHS is accelerating the programme's rollout to ensure all babies born in England are offered this screening by 2028.

Clare Livingstone, head of professional policy and practice at the Royal College of Medicine, noted the important role midwives play in supporting parents' understanding of newborn screening tests. Giles Lomax, SMA UK chief executive, expressed that the trial is a significant step forward for families affected by SMA, providing thousands of babies each year with the opportunity for earlier diagnosis and life-changing treatment before irreversible damage occurs.

What Happens Next

The national trial will continue with the phased addition of laboratories across England. The UK National Screening Committee will review the gathered evidence to decide on the permanent inclusion of SMA screening in the national newborn blood spot test programme. The aim is for all babies born in England to be offered this screening by spring 2028.